Keyword Search
Legend:
CC = Vancouver Convention Centre F = Fairmont Waterfront Vancouver
* = applied session ! = JSM meeting theme
|
Keyword Search Criteria: sample size returned 62 record(s)
|
|
Sunday, 07/29/2018
|
Sample Size Requirements for Estimating L-Moments
Timothy Anderson, Air Force Institute of Technology; Christine M Schubert, Air Force Institute of Technology; Fairul Mohd-Zaid, Air Force Research Lab
|
Sample Size Calculations for Non-Inferiority Trials Using the Concept of Proportional Time
Milind A Phadnis, University of Kansas Medical Center
|
Sample Size Requirements for Estimating L-Moments
Timothy Anderson, Air Force Institute of Technology; Christine M Schubert, Air Force Institute of Technology; Fairul Mohd-Zaid, Air Force Research Lab
2:25 PM
|
Dealing with Inaccurate Measures of Size in Two-Stage Probability Proportional to Size Sample Designs: Applications in African Household Surveys
Graham Kalton, Westat; Ismael Flores Cervantes, Westat; Carlos Arieira, Westat; Mike Kwanisai, Westat; Jehun Kim, Westat; Elizabeth Radin, ICAP at Columbia University; Suzue Saito, ICAP at Columbia University; Anindya De, U.S. Centers for Disease Control and Prevention; Stephen McCracken, U.S. Centers for Disease Control and Prevention; Paul Stupp, U.S. Centers for Disease Control and Prevention
3:20 PM
|
Sample Size Calculations for Non-Inferiority Trials Using the Concept of Proportional Time
Milind A Phadnis, University of Kansas Medical Center
3:25 PM
|
A Gate-Keeping Test for Selecting Adaptive Interventions for Depression Management Under General SMART Designs
Xiaobo Zhong, Columbia University; Bin Cheng, Columbia University; Min Qian, Columbia University; Ying Kuen Ken Cheung, Columbia University
4:20 PM
|
Sample Size and Power Calculation for Immuno-Oncology Clinical Trials
Binbing Yu, MedImmune, Inc.; Dongyue FU, MedImmune, Inc.; Hefei (Harry) Yang, MedImmune, Inc.
4:20 PM
|
Sample Size and Power Analysis for RNA-Seq Differential Expression in Paired Study Designs
Masha Kocherginsky, Northwestern University; Kwang-Youn Kim, Northwestern University ; Daniela E Matei, Northwestern University
4:45 PM
|
|
Monday, 07/30/2018
|
Using the SAS Hash Object for Sample Allocation Procedures with Large Data Sets/Big Data
Julia Batishev, National Opinion Research Center (NORC); Michael Yang, NORC
|
Random Dual Rotation: Generalized Permutation Test for High Dimension, Low Sample Size Data
Hee Cheol Chung, University of Georgia; Jeongyoun Ahn, University of Georgia
|
Power and Sample Size Requirements for GEE Analyzes of Cluster Randomized Crossover Trials
Fan Li, Duke Univeristy; Andrew Forbes, Monash University; Elizabeth L. Turner, Duke Global Health Institutes; John S. Preisser, University of North Carolina at Chapel Hill
|
Comparison of Empirical Size and Power of Goodness-of-Fit Tests for Multiple Logistic Regression Model Under Varied Sample Size Conditions
Pengcheng Lu; Jonathan D Mahnken, University of Kansas Medical Center
9:05 AM
|
Sample Size Considerations for Comparing Dynamic Treatment Regimens in a Sequential Multiple-Assignment Randomized Trial with a Continuous Longitudinal Outcome
Nicholas J Seewald, University of Michigan; Kelley M Kidwell, University of Michigan; James R McKay, University of Pennsylvania; Inbal Nahum-Shani, University of Michigan; Daniel Almirall, University of Michigan
9:35 AM
|
Achieving Optimal Power of Logrank Test with Random Treatment Time-Lag Effect
Zhenzhen Xu , FDA; Yongsoek Park, Unversity of Pittsburgh; Boguang Zhen, FDA; Bin Zhu, NIH/NCI
11:00 AM
|
Power and Sample Size Requirements for GEE Analyzes of Cluster Randomized Crossover Trials
Fan Li, Duke Univeristy; Andrew Forbes, Monash University; Elizabeth L. Turner, Duke Global Health Institutes; John S. Preisser, University of North Carolina at Chapel Hill
11:30 AM
|
Sample Size Calculation for Pilot Studies
Chi-Hong Tseng, UCLA; Danielle SIM, UCLA
2:15 PM
|
Determine Appropriate Sample Size for a Biomarker Signature Discovery Problem Using Penalized Regression
Xiang Li, Statistics and Decision Sciences, Janssen Research & Development, LLC; Hong Tian, Janssen Pharmaceutical; Liang Xiu, Janssen Research & Development, LLC
2:20 PM
|
Sample Size Determination Under Non-Proportional Hazards
Zhaowei Hua, Takeda Pharmaceuticals International Co.; Miao Yang, Oregon State University; Saran Vardhanabhuti, Takeda Pharmaceuticals
2:20 PM
|
'sTATISTICAL JUSTIFICATION' of SUBJECT NUMBERS in PRECLINICAL BIOMEDICAL RESEARCH: MORE THAN HYPOTHESIS TESTING
Penny Reynolds
3:05 PM
|
Prediction Using Machine Learning Algorithms by Small Sample Size Data
Yan Wang, Field School of Public Health, UCLA; Honghu Liu, UCLA; Jian L Zhang, Kaiser Permanente
3:20 PM
|
Powering Biomarker Discovery Studies for Training and Validation
Olga Demler, Harvard Medical School; Nancy R Cook, Harvard Medical School
3:35 PM
|
|
Tuesday, 07/31/2018
|
Sample Size and Assurance Probability Calculation in Multi-Regional Clinical Trials
Zuoshun Zhang, Celgene Corporation
|
Optimal Sample Size for Cluster Randomized Trials: a Simulation-Based Search Algorithm
Ruoshui Zhai, Brown University; Roee Gutman, Brown University
|
Sample Size Calculation for a Pilot Study
Danielle Sim, UCLA; Chi-Hong Tseng, UCLA
|
Sample Size in Adaptive Design with Treatment Selection
Zejiang Yang, Syneos Health
|
Sample Size Calculation for Pilot Studies
Chi-Hong Tseng, UCLA; Danielle SIM, UCLA
|
Determine Appropriate Sample Size for a Biomarker Signature Discovery Problem Using Penalized Regression
Xiang Li, Statistics and Decision Sciences, Janssen Research & Development, LLC; Hong Tian, Janssen Pharmaceutical; Liang Xiu, Janssen Research & Development, LLC
|
Some T-Tests for N-Of-1 Trials with Serial Correlation: Correction Factors for Trials with Few Observations
Reid D. Landes, University of Arkansas for Medical Sciences; Ji-Ling Tang, University of Arkansas for Medical Sciences; Mark S Mennemeier, University of Arkansas for Medical Sciences; J. Tyler Floyd, University of Central Arkansas; Anne Holbrook, McMaster University
|
Parameter Estimate Bias Resulting from Level 3 Sample Size Decisions
Tingqiao Chen; Frank Lawrence, Michigan State University; Wenjuan Ma, Michigan State University
|
Application of External Concordance Method
Wenliang Yao, Astrazeneca; Pralay Mukhopadhyay, Astrazeneca
|
Complexity of Implementing Sample Size Re-Estimation (SSR) in Oncology Trials
Alicia Zhang, Amgen; Yuqi Chen, Amgen; Chris Holland, Amgen
8:35 AM
|
Application of External Concordance Method
Wenliang Yao, Astrazeneca; Pralay Mukhopadhyay, Astrazeneca
9:40 AM
|
Weighted Averages for Reconstructed Pathways: a Novel Method for Pathway Level Analysis of Gene Expression Profiles
Monnie McGee, Southern Methodist University; Elizabeth McClellan, Metropolitan State University of Denver; Richard H Scheuermann, J Craig Venter Institute
10:05 AM
|
Simple Bootstrap and Simulation Approaches to Quantifying Reliability of High-Dimensional Feature Selection
Frank Harrell, Vanderbilt University, Dept of Biostatistics
10:35 AM
|
Some T-Tests for N-Of-1 Trials with Serial Correlation: Correction Factors for Trials with Few Observations
Reid D. Landes, University of Arkansas for Medical Sciences; Ji-Ling Tang, University of Arkansas for Medical Sciences; Mark S Mennemeier, University of Arkansas for Medical Sciences; J. Tyler Floyd, University of Central Arkansas; Anne Holbrook, McMaster University
10:40 AM
|
Nested Subsamples: a Method for Achieving Flexibility in Annual Sample Sizes for a Continuous Multiyear Survey
Van Parsons, National Center for Health Statistics; Chris Moriarity, National Center for Health Statistics
10:50 AM
|
A Robust Approach to Sample Size Calculation in Cancer Immunotherapy Trials with Delayed Treatment Effect
Ting Ye, University of Wisconsin-Madison; Menggang Yu, University of Wisconsin-Madison
10:55 AM
|
Parameter Estimate Bias Resulting from Level 3 Sample Size Decisions
Tingqiao Chen; Frank Lawrence, Michigan State University; Wenjuan Ma, Michigan State University
11:45 AM
|
|
Wednesday, 08/01/2018
|
Incorporating Intermediate Binary Responses into Interim Analysis of a Long-Term Binary Endpoint
Andrejus Parfionovas, Takeda Pharmaceuticals; Jingjing Chen, Takeda Pharmaceuticals; Tina Liu, Takeda Pharmaceuticals; Cong Han, Takeda Pharmaceuticals; Xiaopan Yao, Takeda Pharmaceuticals
|
Further Extensions of the Two-Stage Randomized Trial Design for Testing Treatment, Self-Selection and Treatment Preference Effects to Include Count Outcomes
Denise Esserman, Yale University; Yu Shi, Yale University
|
Sample Size Estimation for Stratified Cluster Randomized Trials with Binary Outcomes
Lee Kennedy-Shaffer, Harvard University; Michael David Hughes, Harvard University
|
Sample Size Formulae and Application for the Two-Stage Continual Reassessment Method (CRM)
Cody Chiuzan, Columbia University; Ying Kuen Ken Cheung, Columbia University; Zilan Chai, Columbia University
|
A Two-Stage, Phase II Clinical Trial Design with Nested Criteria for Early Stopping and Efficacy: Expected Trial Duration and Tools for Planning
Michelle DeVeaux, Regeneron Pharmaceuticals; Michael John Kane, Yale University; Daniel Zelterman, Yale University
|
Sample Size Allocation in Multi-Regional Equivalence Studies
Jason Liao, Merck & Co. Inc.; Ziyi Yu, Jazz Pharmaceuticals Inc; Yulan Li, Myovant Sciences
8:50 AM
|
Sample Size Formulae and Application for the Two-Stage Continual Reassessment Method (CRM)
Cody Chiuzan, Columbia University; Ying Kuen Ken Cheung, Columbia University; Zilan Chai, Columbia University
8:55 AM
|
BLINDED SAMPLE SIZE RE-ESTIMATION
Chien-Hua Wu, Chung-Yuan Christian University; Shu-Mei Wan, Lunghwa University of Science and Technology
9:05 AM
|
Incorporating Intermediate Binary Responses into Interim Analysis of a Long-Term Binary Endpoint
Andrejus Parfionovas, Takeda Pharmaceuticals; Jingjing Chen, Takeda Pharmaceuticals; Tina Liu, Takeda Pharmaceuticals; Cong Han, Takeda Pharmaceuticals; Xiaopan Yao, Takeda Pharmaceuticals
9:10 AM
|
Bayesian Blinded Sample Size Adjustment for Risk Differences
Andrew Hartley, PPD, Inc.
9:15 AM
|
Multivariate Output Analysis for Markov Chain Monte Carlo
James Flegal, University of California, Riverside
9:15 AM
|
Further Extensions of the Two-Stage Randomized Trial Design for Testing Treatment, Self-Selection and Treatment Preference Effects to Include Count Outcomes
Denise Esserman, Yale University; Yu Shi, Yale University
9:20 AM
|
Sample Size Estimation for Stratified Cluster Randomized Trials with Binary Outcomes
Lee Kennedy-Shaffer, Harvard University; Michael David Hughes, Harvard University
9:30 AM
|
Weighted Log-Rank Test for Time-To-Event Data in Immunotherapy Trials with Random Delayed Treatment Effect and Cure Rate
Shufang Liu, Astellas Pharma; Chenghao Chu, Indiana University, Fairbanks School of Public Health; Alan Rong, Data Science, Astellas Pharma Inc.
9:35 AM
|
Blinded vs. Unblinded Sample Size Re-Estimation: When and What?
Yili Pritchett, MedImmune
9:35 AM
|
A Two-Stage, Phase II Clinical Trial Design with Nested Criteria for Early Stopping and Efficacy: Expected Trial Duration and Tools for Planning
Michelle DeVeaux, Regeneron Pharmaceuticals; Michael John Kane, Yale University; Daniel Zelterman, Yale University
9:50 AM
|
Estimating Probability of Simultaneous Success with Multiple Endpoints Using Truncated Multi-Variate Correlated Normal Distribution
Tianshuang Wu, AbbVie; Yihua Gu, AbbVie; Ziqian Geng, AbbVie; Saurabh Mukhopadhyay, AbbVie
10:50 AM
|
On Randomized Controlled Trials with Integrated Real World Evidence for Drug Development in Rare Diseases
Qing Liu, Amicus Therapeutics, Inc
11:15 AM
|
Degrees of Freedom Adjustment in Mixed Model Repeated Measures Analyzes with Missing Data
Michael McDermott, University of Rochester Medical Center; Madhurima Majumder, Bayer Pharmaceuticals
2:05 PM
|
Considerations in Designing the 2020 Post-Enumeration Survey Sample
Laura A. Davis, US Census Bureau; T. Trang Nguyen, US Census Bureau; Courtney Hill, U.S. Census Bureau
2:25 PM
|
DiPhiSeq: Robust Comparison of Expression Levels on RNA-Seq Data with Large Sample Sizes
Alicia Lamere, Bryant University; Jun Li, University of Notre Dame
2:35 PM
|
|
Thursday, 08/02/2018
|
Evaluating Biomarkers for Prognostic Enrichment of Clinical Trials
Kathleen F. Kerr, University of Washington; Jeremy Roth, University of Washington; Kehao Zhu, Axio Research; Heather Thiessen-Philbrook, Yale University; Allison Meisner, Johns Hopkins University; Francis Perry Wilson, Yale University; Steven Coca, Icahn School of Medicine at Mount Sinai; Chirag Parikh, Yale University
10:35 AM
|
On Sample Size Requirement for Analytical Similarity Assessment
Victoria Chang, AbbVie; Yi Zhao, Statistics Collaborative; Shein-Chung Chow, Food and Drug Administration
10:50 AM
|
Practical Considerations of Subgroups Quantification, Selection and Adaptive Enrichment in Confirmatory Trials
Jianchang Lin, Takeda Pharmaceuticals; Rachael Liu, Takeda Pharmaceuticals ; Veronica Bunn, Florida State University
11:20 AM
|
|
|
